Clexio is a clinical-stage company designing novel drugs based on validated MOAs in Psychiatry and Neurology.
We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder, Schizophrenia and Peripheral Neuropathy.
Our lead drug candidates (CLE-100 and CLE-400) are currently being tested in Phase 2 multicenter studies in the United States.
Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages, and regulatory approvals.
Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for patients.
